Pathogen Inactivation Technologies: The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk

Hematology/Oncology Clinics of North America

Volumn 30, Issue 3, 2016, Pages 609-617

  Devine, Dana V ^a,b   Schubert, Peter ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Blood safety; Blood transfusion; Pathogen inactivation; Pathogen reduction technology

Indexed keywords

AMOTOSALEN; FRESH FROZEN PLASMA; METHYLENE BLUE; RIBOFLAVIN; SOLVENT;

BACTERIAL COUNT; BACTERIUM CONTAMINATION; BLOOD ANALYSIS EQUIPMENT; BLOOD DONOR; BLOOD EXAMINATION; BLOOD SAFETY; BLOOD TRANSFUSION; CREUTZFELDT JAKOB DISEASE; CROSS LINKING; DISEASE TRANSMISSION; ERYTHROCYTE; GLUCOSE METABOLISM; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; INFECTION RISK; LEUKOCYTE; PHOTOACTIVATION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SCREENING TEST; THROMBOCYTE ACTIVATION; VIRUS TRANSMISSION; DISINFECTION; PLASMA; PROCEDURES; QUALITY CONTROL; RISK FACTOR; THROMBOCYTE TRANSFUSION;

BLOOD SAFETY; DISINFECTION; HUMANS; PLASMA; PLATELET TRANSFUSION; QUALITY CONTROL; RISK FACTORS;

EID: 84963973929     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2016.01.005     Document Type: Review

References (54)

1. Dwyre D.M., Fernando L.P., Holland P.V. Hepatitis B, Hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 2011, 100:92-98.
2. Vamvakas E.C., Blajchman M.A. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010, 24:77-124.
3. Iudicone P., Miceli M., Palange M., et al. Hepatitis B virus blood screening: impact of nucleic amplification technology testing implementation on identifying hepatitis B surface antigen non-reactive window period and chronic infections. Vox Sang 2009, 96:292-297.
4. Weusten J., Vermeulen M., van Drimmelen H., et al. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion 2011, 51:203-215.
5. Dodd R., Kurt Roth W., Ashford P., et al. Transfusion medicine and safety. Biologicals 2009, 37:62-70.
6. McDonald C.P. Bacterial risk reduction by improved donor arm disinfection, diversion and bacterial screening. Transfus Med 2006, 16:381-396.
7. Vasconcelos E., Seghatchian J. Bacterial contamination in blood components and preventative strategies: an overview. Transfus Apher Sci 2004, 31:155-163.
8. Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011, 100:169-178.
9. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004, 11:346-350.
10. Burnouf T., Radosevich M., El-Ekiaby M., et al. Pathogen reduction technique for fresh-frozen plasma, cryoprecipitate, and plasma fraction minipools prepared in disposable processing bag systems. Transfusion 2011, 51:446-447.
11. Seghatchian J., Struff W.G., Reichenberg S. Main properties of the THERAFLEX MB-plasma system for pathogen reduction. Transfus Med Hemother 2011, 38:55-64.
12. Irsch J., Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfus Med Hemother 2011, 38:19-31.
13. Ciaravino V., McCullough T., Cimino G., et al. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang 2003, 85:171-182.
14. Reikvam H., Marschner S., Apelseth T.O., et al. The mirasol pathogen reduction technology system and quality of platelets stored in platelet additive solution. Blood Transfus 2010, 8:186-192.
15. Seghatchian J., Walker W.H., Reichenberg S. Updates on pathogen inactivation of plasma using Theraflex methylene blue system. Transfus Apher Sci 2008, 38:271-280.
16. Seltsam A., Muller T.H. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011, 38:43-54.
17. Coene J., Devreese K., Sabot B., et al. Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction. Transfusion 2014, 54:1321-1331.
18. Wagner S.J. Developing pathogen reduction technologies for RBC suspensions. Vox Sang 2011, 100:112-121.
19. Henschler R., Seifried E., Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011, 38:33-42.
20. Zavizion B., Pereira M., de Melo Jorge M., et al. Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry. Transfusion 2004, 44:731-738.
21. Cancelas J.A., Dumont L.J., Rugg N., et al. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion 2011, 51:2367-2376.
22. Winter K.M., Johnson L., Kwok M., et al. Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment. Transfusion 2014, 54:1798-1807.
23. Ciaravi V., McCullough T., Dayan A.D. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 2001, 20:533-550.
24. Mirasol Clinical Evaluation Study Group A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010, 50:2362-2375.
25. Osselaer J.C., Messe N., Hervig T., et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008, 48:1061-1071.
26. van Rhenen D., Gulliksson H., Cazenave J.P., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003, 101:2426-2433.
27. Mohr H., Gravemann U., Muller T.H. Inactivation of pathogens in single units of therapeutic fresh plasma by irradiation with ultraviolet light. Transfusion 2009, 49:2144-2151.
28. Mohr H., Steil L., Gravemann U., et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009, 49(12):2612-2624.
29. Thiele T., Pohler P., Kohlmann T., et al. Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction - a phase I clinical trial. Vox Sang 2015, 109:44-51.
30. Cancelas J.A., Rugg N., Fletcher D., et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011, 51:1460-1468.
31. Marschner S., Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011, 38:8-18.
32. Mufti N.A., Erickson A.C., North A.K., et al. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010, 38:14-19.
33. Fast L.D., Nevola M., Tavares J., et al. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease?. Transfusion 2013, 53:373-381.
34. Schubert P., Culibrk B., Karwal S., et al. Whole blood treated with riboflavin/UV light: quality assessment of all blood components produced by the buffy coat method. Transfusion 2015, 55:815-823.
35. Kwon S.Y., Kim I.S., Bae J.E., et al. Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 2014, 107:254-260.
36. Brecher M.E., Hay S.N. Bacterial contamination of blood components. Clin Microbiol Rev 2005, 18:195-204.
37. Singh Y., Sawyer L.S., Pinkoski L.S., et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006, 46:1168-1177.
38. Tonnetti L., Proctor M.C., Reddy H.L., et al. Evaluation of the Mirasol pathogen reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010, 50:1019-1027.
39. Cardo L.J., Salata J., Mendez J., et al. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007, 37:131-137.
40. Cardo L.J., Rentas F.J., Ketchum L., et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang 2006, 90:85-91.
41. Rentas F., Harman R., Gomez C., et al. Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model. Transfusion 2007, 47:240-247.
42. Schlenke P. Pathogen inactivation technologies for cellular blood products: an update. Transfus Med Hemother 2014, 41:309-325.
43. Doyle S., O'Brien P., Murphy K., et al. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 2003, 14:283-287.
44. Hellstern P., Sachse H., Schwinn H., et al. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 1992, 63:178-185.
45. Piquet Y., Janvier G., Selosse P., et al. Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang 1992, 63:251-256.
46. Ostrowski S.R., Bochsen L., Windelov N.A., et al. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010, 51:344-356.
47. Picker S.M., Speer R., Gathof B.S. Evaluation of processing characteristics of photochemically treated pooled platelets: target requirements for the INTERCEPT Blood System comply with routine use after process optimization. Transfus Med 2004, 14:217-223.
48. Picker S.M., Steisel A., Gathof B.S. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008, 48:1685-1692.
49. AuBuchon J.P., Herschel L., Roger J., et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005, 45:1335-1341.
50. McCullough J., Vesole D.H., Benjamin R.J., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004, 104:1534-1541.
51. Lozano M., Knutson F., Tardivel R., et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011, 153:393-401.
52. Osselaer J.C., Doyen C., Defoin L., et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009, 49:1412-1422.
53. Sigle J.P., Infanti L., Studt J.D., et al. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components. Transfusion 2013, 53:1788-1797.
54. Kaiser-Guignard J., Canellini G., Lion N., et al. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 2014, 28:235-241.